Company Overview of Fresenius Kabi USA, LLC
Fresenius Kabi USA, LLC develops, manufactures, and delivers pharmaceuticals and medical devices for critically and chronically ill patients. The company specializes in lifesaving medicines and technologies for infusion, transfusion, and clinical nutrition. It offers pharmaceuticals used in the treatment of various therapeutic areas, such as anti-infective, anesthesia/analgesia, critical care, and oncology for hospitals, long-term care facilities, alternate care sites, and clinics in North America. The company also provides medical devices in the areas of transfusion technologies, infusion pumps, therapeutic apheresis, plasmapheresis system, and cell processing. It sells its products through...
3 Corporate Drive
Lake Zurich, IL 60047
Founded in 1996
Key Executives for Fresenius Kabi USA, LLC
Chief Executive Officer and President
Chief Financial Officer and Executive Vice President
Chief Operating Officer and Executive Vice President
President of Pharmaceuticals of North America Region
President of Medical Devices - Region North America
Compensation as of Fiscal Year 2015.
Fresenius Kabi USA, LLC Key Developments
Fresenius Kabi USA Appoints Seema Kumbhat as Senior Vice President and Medical Director
Feb 9 16
Fresenius Kabi USA announced that Seema Kumbhat, M.D., has joined the company as senior vice president and medical director. Dr. Kumbhat reports to John Ducker, president and CEO of Fresenius Kabi USA, and is a new member of the company’s executive committee. Dr. Kumbhat and her team will be responsible for pre-and post-launch clinical and medical strategies; clinically focused training and education and scientific exchange with stakeholders in the medical community. Dr. Kumbhat has more than 20 years of experience in health care. Before joining Fresenius Kabi, she held similar roles of increasing responsibility at Hospira, where she was global medical director, biosimilars, in clinical development and medical affairs and medical director, device development.
BD and Fresenius Kabi Announce Supply and Distribution Agreement
Jan 8 16
BD (Becton, Dickinson and Company) announced that Fresenius Kabi USA has acquired the BD Rx business, which includes a pharmaceutical manufacturing plant in Wilson, N.C., and the BD Simplist line of seven drugs in ready-to-administer prefilled glass syringes. BD and Fresenius Kabi have signed a 10-year supply and distribution agreement under which Fresenius Kabi will supply BD with a portfolio of intravenous solutions. Both BD and Fresenius Kabi plan to offer a range of IV solutions in the U.S. beginning in 2016.
Fresenius Kabi USA Introduces Moxifloxacin Injection 400 mg per 250 mL in Freeflex Bags
Sep 11 15
Fresenius Kabi USA introduced the anti-infective Moxifloxacin Injection 400 mg per 250 mL in Freeflex bags. The anti-infective Moxifloxacin Injection 400 mg per 250 mL is now available in the U.S. from Fresenius Kabi. Moxifloxacin is the third premix product Fresenius Kabi has introduced in the United States since 2013 using the company’s proprietary Freeflex delivery system. Freeflex is a non-PVC and non-DEHP flexible bag for infusion solutions using patented port technology and clear labeling. Moxifloxacin injection is indicated for the treatment of adults (18 years of age or older) with infections caused by susceptible isolates of the designated microorganisms in the conditions listed. Acute Bacterial Sinusitis; Acute Bacterial Exacerbation of Chronic Bronchitis; Community Acquired Pneumonia; Uncomplicated Skin and Skin Structure Infections; Complicated Skin and Skin Structure Infections; and Complicated Intra-Abdominal Infections.
Similar Private Companies By Industry
Recent Private Companies Transactions